Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375571 | 0.90 | MTNR1A (0.58) | MTNR1APLA2G4B | |
| SCHEMBL249940 | 0.90 | CNR1 (0.48) | MTNR1APTGS2PPARGPPARA | |
| SCHEMBL27527363 | 0.89 | MTNR1A (0.60) | MTNR1APTGS2PLA2G4BSMPD1 | |
| SCHEMBL27343133 | 0.87 | MTNR1A (0.55) | MTNR1ATHRB | |
| SCHEMBL249286 | 0.85 | KCNA3 (0.55) | — | |
| SCHEMBL15772640 | 0.82 | KCNA3 (0.54) | — | |
| SCHEMBL29447160 | 0.82 | KCNA3 (0.54) | — | |
| SCHEMBL9476254 | 0.82 | KDM4E (0.50) | MTNR1A | |
| SCHEMBL27524529 | 0.82 | MTNR1A (0.54) | MTNR1A | |
| SCHEMBL13133137 | 0.80 | PDGFRB (0.47) | MTNR1APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | MTNR1A 113/4885PTGS2 803/4885PLA2G4B 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.